UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 15, 2015
American CareSource Holdings, Inc.
(Exact name of registrant as specified in charter)
Delaware | 001-33094 | 20-0428568 |
(State or other jurisdiction | (Commission | (IRS Employer |
of incorporation) | File Number) | Identification No.) |
1170 Peachtree Street, Suite 2350 Atlanta, Georgia 30309 |
(Address of Principal Executive Offices) |
(404) 465-1000 |
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, If Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01. | Entry Into a Material Definitive Agreement. |
As previously reported, on July 31, 2015, ACSH Medical Management, LLC (“ACSH Management”), a wholly-owned subsidiary of the registrant, American CareSource Holdings, Inc. (the “Company”), entered into an asset purchase agreement (as amended, the “Asset Purchase Agreement”) with Medac Health Services, P.A. (“Medac”) and its shareholders to purchase certain assets used by Medac in the operation of its four urgent care centers in the greater Wilmington, North Carolina area (the foregoing transaction, the “Medac Asset Acquisition”). On December 15, 2015, the Medac Asset Acquisition was consummated.
At closing, and pursuant to the terms of the Asset Purchase Agreement, ACSH Management agreed to, among other things, (a) lease the purchased assets back to Medac, (b) assume or enter into new leases for the four centers and sublease them to Medac and (c) enter into a management services agreement with Medac. Medac retains control over all of the clinical aspects of the urgent care business, including the employment or engagement of all individuals whose duties include the rendition of medical care.
Under the terms of the management services agreement (the “Management Services Agreement”) entered into between Medac and ACSH Management on December 15, 2015, ACSH Management agreed to manage the non-clinical operations of the Medac centers and to assist in Medac’s provision of administrative and staffing services to an emergency medicine physician group, each in exchange for a fixed management fee, which fee may be adjusted by ACSH Management no more frequently than annually. The initial term of the Management Services Agreement is 10 years from the closing date, with an automatic renewal of 5 additional years unless either party provides written notice to the other at least 180 days before the expiration of the initial term. The Management Services Agreement also contains customary confidentiality, termination and indemnification provisions.
The foregoing description of the Asset Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Asset Purchase Agreement, a copy of which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “Commission”) on August 6, 2015 and is hereby incorporated by reference. The foregoing description of the Management Services Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Management Services Agreement, a copy of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ending December 31, 2015.
Item 2.01. | Completion of Acquisition or Disposition of Assets. |
The information set forth under Item 1.01 above is incorporated by reference into this Item 2.01.
Pursuant to the Asset Purchase Agreement, the purchase price for the Medac Asset Acquisition was $5.7 million, with approximately $5.1 million payable in cash at closing and the balance of approximately $0.6 million payable in the form of a promissory note.
Certain financial statements and other information of Medac and the Company are filed herewith as Exhibits 99.1-99.3, and are incorporated herein by reference.
Item 2.03. | Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. |
The information set forth under Items 1.01 and 2.01 above are incorporated by reference into this Item 2.03.
1 |
In connection with the partial payment of the purchase price for the Medac Asset Acquisition, on December 15, 2015, a promissory note in the original principal amount of $560,000 was executed by ACSH Management in favor of Medac, with interest accruing at 5% per annum and maturing on June 15, 2017.
The foregoing description of the promissory note does not purport to be complete and is qualified in its entirety by the full text of the promissory note which is filed herewith as Exhibit 10.1 and incorporated herein by reference.
Item 9.01. | Financial Statements and Exhibits. |
(a) Financial statements of businesses acquired.
(b) Pro forma financial information.
(d) Exhibits.
Exhibit No. | Description | |
2.1 | Asset Purchase Agreement, dated as of July 31, 2015, among Medac Health Services, P.A., the shareholders of Medac Health Services, P.A., Kevin E. Potts, MD, and ACSH Medical Management, LLC (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-33094) filed with the Commission on August 6, 2015). | |
10.1 | Promissory Note, dated as of December 15, 2015, between ACSH Medical Management, LLC and Medac Health Services, P.A. | |
23.1 | Consent of LWBJ LLP. | |
99.1 | Audited Medac Health Services, P.A. Financial Statements and Supplemental Information as of and for the years ended December 31, 2014 and 2013. | |
99.2 | Unaudited Medac Health Services, P.A. Financial Statements and Supplemental Information, as of and for the nine months ended September 30, 2015. | |
99.3 | Unaudited Pro Forma Financial Information of American CareSource Holdings, Inc. for the year ended December 31, 2014 and as of and for the nine months ended September 30, 2015. |
2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 15, 2015
American CareSource Holdings, Inc. | ||
By: | /s/ Adam S. Winger | |
Adam S. Winger | ||
General Counsel, Secretary, Vice President of Acquisitions and Interim Chief Financial Officer |
3 |
EXHIBIT INDEX
Exhibit No. | Description | |
2.1 | Asset Purchase Agreement, dated as of July 31, 2015, among Medac Health Services, P.A., the shareholders of Medac Health Services, P.A., Kevin E. Potts, MD, and ACSH Medical Management, LLC (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-33094) filed with the Commission on August 6, 2015). | |
10.1 | Promissory Note, dated as of December 15, 2015, between ACSH Medical Management, LLC and Medac Health Services, P.A. | |
23.1 | Consent of LWBJ LLP. | |
99.1 | Audited Medac Health Services, P.A. Financial Statements and Supplemental Information as of and for the years ended December 31, 2014 and 2013. | |
99.2 | Unaudited Medac Health Services, P.A. Financial Statements and Supplemental Information, as of and for the nine months ended September 30, 2015. | |
99.3 | Unaudited Pro Forma Financial Information of American CareSource Holdings, Inc. for the year ended December 31, 2014 and as of and for the nine months ended September 30, 2015. |
4 |
Exhibit 10.1
PROMISSORY NOTE
$560,000 | December 15, 2015 |
FOR VALUE RECEIVED, ACSH MEDICAL MANAGEMENT, LLC, a Delaware limited liability company (“Borrower”), hereby promises to pay to MEDAC HEALTH SERVICE, P.A., a North Carolina professional corporation (“Lender”), to the address Medac Health Services, P.A., 4402 Shipyard Blvd., Wilmington, NC 28403 or at such other place as may be designated in writing by Lender, the principal sum of $560,000, together with interest on the unpaid balance thereof at the rate, on the terms and subject to the conditions set forth herein.
This Promissory Note (this “Note”) is delivered by Borrower pursuant to and in accordance with the terms and conditions of that certain Asset Purchase Agreement (the “Purchase Agreement”), dated as of July 31, 2015, by and among Borrower, Lender, each shareholder of Lender, and Kevin E. Potts, MD, as representative of such shareholders (Lender and such shareholders, collectively, “Seller Parties”). Capitalized terms used and not otherwise defined in this Note shall have the meanings ascribed to such term in the Purchase Agreement.
1. Interest Rate. The unpaid principal balance of the Note shall bear simple interest starting on the date hereof at a fixed interest rate of 5% per annum. After the Maturity Date (defined below) or the date of an Event of Default (defined below), whichever occurs first, the principal balance hereof and any other amounts due hereunder shall bear interest at the rate of twelve percent (12%) per annum until paid in full. In no event shall the amount of interest due or payable under this Note exceed the maximum rate of interest allowed by applicable law, as amended from time to time. If any payment of interest or in the nature of interest would, under applicable Law, cause the foregoing interest rate limitation to be exceeded, then the excess payment shall be credited as a payment of principal, unless Borrower notifies Lender that Borrower desires to have the excess sum returned to Borrower.
2. Maturity. If not sooner prepaid pursuant to the terms of this Note, and subject to earlier acceleration in accordance with Section 6 below, the unpaid principal balance and all accrued but unpaid interest under this Note shall be due and payable on the date that is 18 months after the date of this Note (the “Maturity Date”); provided that if Borrower in good faith delivers to Lender an indemnity notice pursuant to Section 6.11 of the Purchase Agreement prior to the Maturity Date, and the matters for which indemnification is sought are unresolved on the Maturity Date, the Maturity Date for an amount equal to the amount for which indemnification is sought shall be the date that is fifteen days after the date all such matters are finally and fully resolved (for the avoidance of doubt, the Maturity Date for any amount in excess of the amount for which indemnification is sought shall be unaffected by this proviso).
3. Prepayment. The principal amount of this Note may be prepaid in full or in part at any time without penalty. Any such prepayment shall be first applied to accrued but unpaid interest, and the balance, if any, to principal.
4. Security for Loan. This Note is secured by the unconditional and absolute guaranty of payment given by American CareSource Holdings, Inc. (“Guarantor”) to Lender pursuant to the Guaranty dated of even date herewith (the “Guaranty”).
1 |
5. Event of Default. An “Event of Default” shall occur under this Note upon the happening of any one or more of the following events: (a) the failure of Borrower to pay all amounts when due on or before the applicable Maturity Date determined in accordance with Section 2; (b) the making by Borrower or Gurantor of a general assignment for the benefit of creditors; (c) the filing of a petition or the commencement of any proceeding by or against Borrower or any endorser or Guarantor for any relief under any bankruptcy or insolvency laws, or any law relating to the relief of debtors, readjustment of indebtedness, reorganization, consolidations or extensions; (d) Borrower’s or Guarantor’s dissolution, liquidation or bankruptcy; (e) the suspension of the transaction of the usual business of Borrower; (f) any sale, exchange or conveyance to another person or entity of all or substantially all of the assets of Borrower or Guarantor (excluding any assets used in connection with Guarantor’s operation of its ancillary network business, which Lender acknowledges that Guarantor intends to sell prior to the Maturity Date) or a sale or transfer of more than fifty percent (50%) of the ownership interest in Borrower or Guarantor, whether by sale, merger or consolidation; and (g) in the event of a breach or default of any representation, warranty or covenant of Borrower or Guarantor set forth in this Note or the Guaranty.
6. Acceleration. Upon the happening of an Event of Default, the entire unpaid principal balance of this Note, together with any accrued interest or other amounts due hereunder, shall immediately become due and payable without notice or demand.
7. Costs of Enforcement; Cumulative Remedies. Upon an Event of Default, the holder of this Note may employ an attorney to enforce the holder’s rights and remedies and Borrower hereby agrees to pay to the holder, in addition to the unpaid principal and interest hereof, to the extent allowed by law, reasonable attorneys’ fees (not exceeding a sum equal to fifteen percent (15%) of the outstanding balance owing on the Note) and costs of collection. The rights and remedies of the holder as provided in this Note or by law shall be cumulative and may be pursued singly, successively or together.
8. Waiver of Notice and Other Rights. Borrower hereby waives presentment for payment, demand, protest, notice of nonpayment or dishonor, and any and all other notices and demands whatsoever, and any and all defenses on the grounds of (a) any extension of time for payment which may be granted by the holder of this Note, (b) any release, surrender, exchange, modification or substitution of this Note, and (c) any failure to assert any legal rights available to the holder of this Note. Borrower agrees to remain bound until the entire indebtedness evidenced by this Note is paid in full. No waiver by Lender of any right or remedy under this Note shall be effective unless in writing signed by Lender. Neither the failure nor the delay in enforcing any right, power or privilege under this Note will operate as a waiver or release of any such right, power or privilege and no single or cumulative exercise of any such right, power or privilege by Lender will preclude any other or further exercise of such right, power or privilege or the exercise of any other right, power or privilege. To the maximum extent permitted by law, (1) no claim or right of Lender arising out of this Note can be discharged by Lender, in whole or in part, by a waiver or renunciation of the claim or right unless in a writing signed by Lender; (2) no waiver that may be given to Borrower will be applicable except in the specific instance for which it is given; and (3) no notice to or demand on Borrower will be deemed to be a waiver of any obligation of Borrower or of the right of Lender to take further action without notice or demand as provided in this Note.
9. Method of Payment. Payments made pursuant to this Note shall be made in cash or immediately available funds to Lender at the address provided above, or to such other address as Lender may designate to Borrower in writing from time to time.
10. Offset by Borrower. Borrower may offset undisputed amounts owed to Borrower by any Seller Party under any of the Transaction Documents against any amount owed to Lender under this Note, whether or not such amounts are currently due under this Note; provided that Borrower first comply with all terms and satisfy all conditions set forth in the applicable Transaction Documents.
11. Applicable Law and Dispute Resolution. The provisions set forth in Article 8 of the Purchase Agreement relating to choice of law and dispute resolution shall govern any dispute concerning this Note.
2 |
12. Execution and Delivery. Notwithstanding anything to the contrary set forth herein, this Note shall be executed and delivered at the location designated for Closing in the Purchase Agreement.
13. Headings. The headings of the sections, subsections, paragraphs and subparagraphs of this Note are used only for convenience of reference and shall not be considered in construing the contents of this Note.
14. Severability. No determination by any court, agency or other Governmental Authority that any provision of this Note is invalid or unenforceable in any instance shall affect the validity or enforceability of (a) any other such provision or (b) such provision in any circumstance not controlled by such determination. Each such provision shall be valid and enforceable to the fullest extent allowed by, and shall be construed wherever possible as being consistent with, applicable law.
15. Modification. This Note may be modified, amended, discharged or waived only by an agreement in writing signed by Borrower and Lender.
16. Not a Negotiable Instrument; Assignment to Thor Management. This Note shall not be deemed to be a negotiable instrument, and the rights and obligations under this Note may not be assigned or delegated by Borrower or any Seller Party without the prior written consent of the other and no such assignment or delegation shall release the liability of the Borrower unless otherwise agreed by Lender in writing. Notwithstanding the foregoing, the Purchase Agreement contemplates Lender’s assignment of this Note to Thor Management, LLC, a North Carolina limited liability company (“Thor Management”)as part of the Transactions; accordingly, Borrower’s consent shall not be required in connection with such assignment and, following such assignment, Thor Management shall have all of the rights of Lender hereunder. This Note shall bind Borrower and Borrower’s successors and permitted assigns, and inure to the benefit of Lender and Lender’s successors and assigns.
17. Notices. All notices and other communications provided for by this Note shall be given in the manner as set forth in the Purchase Agreement and to the parties at their addresses.
18. Time of the Essence. Time is hereby declared to be of the essence of this Note and of every part hereof.
19. Relationship. Nothing contained in this Note shall be deemed or construed to create a partnership, tenancy-in-common, joint tenancy, joint venture or co-ownership by or between Borrower and any Seller Party.
[Signature Page Follows]
3 |
IN WITNESS WHEREOF, the undersigned has executed this Note in favor of Lender as of the date first written above.
BORROWER: | ||
ACSH MEDICAL MANAGEMENT, LLC, | ||
a Delaware limited liability company | ||
By: | /s/ Norman B. Winland |
Name: | Norman B. Winland | |
Title: | President |
4 |
Exhibit 23.1
Consent of Independent Auditors
We hereby consent to the use in this Current Report on Form 8-K (No. 001-33094) of American CareSource Holdings, Inc. of our report dated July 16, 2015, with respect to our audits of the financial statements of Medac Health Services, P.A. for the years ended December 31, 2014 and 2013.
/s/ LWBJ, LLP
West Des Moines, Iowa
December 15, 2015
Exhibit 99.1
To the Shareholders
Medac Health Services, P.A.
Wilmington, North Carolina
We have audited the accompanying financial statements of Medac Health Services, P.A., which comprise the balance sheets as of December 31, 2014 and 2013, and the related statements of income, retained earnings, and cash flows for the years then ended, and the related notes to the financial statements.
Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.
Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entitys preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entitys internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Medac Health Services, P.A., as of December 31, 2014 and 2013, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.
Our audits were conducted for the purpose of forming an opinion on the basic financial statements taken as a whole. The accompanying schedules of other operating expenses are presented for purposes of additional analysis and are not a required part of the basic financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audits of the basic financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the basic financial statements taken as a whole.
/s/ LWBJ, LLP
West Des Moines, Iowa
July 16, 2015
1
2014 | 2013 | |||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents | $ | 721,693 | $ | 324,341 | ||||
Patient accounts receivable, net (Note 2) | 533,573 | 431,477 | ||||||
Receivable from related party (Note 8) | 44,796 | | ||||||
Prepaid insurance | 4,383 | 19,746 | ||||||
Other current assets | 5,036 | 6,943 | ||||||
Total current assets | 1,309,481 | 782,507 | ||||||
Investment in real estate (Note 7) | 155,172 | 155,172 | ||||||
Other assets, noncurrent | 4,008 | 3,107 | ||||||
159,180 | 158,279 | |||||||
Property and equipment: |
||||||||
Leasehold improvements | 1,763,388 | 1,753,453 | ||||||
Furniture | 217,230 | 213,812 | ||||||
Computer equipment | 138,974 | 87,609 | ||||||
Medical equipment | 233,204 | 189,862 | ||||||
Office equipment | 144,920 | 144,855 | ||||||
Other equipment | 121,885 | 32,339 | ||||||
2,619,601 | 2,421,930 | |||||||
Less accumulated depreciation | 1,648,713 | 1,428,072 | ||||||
970,888 | 993,858 | |||||||
Total assets | $ | 2,439,549 | $ | 1,934,644 | ||||
Liabilities and shareholders equity |
||||||||
Current liabilities: |
||||||||
Line of credit (Note 3) | $ | | $ | 85,000 | ||||
Current portion of capital lease obligations (Note 4) | 14,744 | 34,504 | ||||||
Current maturities of long-term debt (Note 3) | 138,848 | 61,648 | ||||||
Accounts payable | 291,503 | 106,280 | ||||||
Accrued salaries, wages, and benefits | 233,496 | 241,763 | ||||||
Other accrued expenses | 202,669 | 193,379 | ||||||
Total current liabilities | 881,260 | 722,574 | ||||||
Capital lease obligations, net of current portion (Note 4) | 54,912 | | ||||||
Long-term debt, less current maturities (Note 3) | 731,530 | 870,378 | ||||||
Total liabilities | 1,667,702 | 1,592,952 | ||||||
Contingency (Note 4) |
||||||||
Shareholders equity: |
||||||||
Common stock, $1 par value; 100,000 shares authorized; 1,200 shares issued and outstanding | 1,200 | 1,200 | ||||||
Additional paid-in capital | 71,913 | 71,913 | ||||||
Retained earnings | 698,734 | 268,579 | ||||||
Total shareholders equity | 771,847 | 341,692 | ||||||
Total liabilities and shareholders equity | $ | 2,439,549 | $ | 1,934,644 |
See accompanying notes.
2
2014 | 2013 | |||||||
Patient service revenue, net (Note 2) | $ | 6,575,495 | $ | 5,654,715 | ||||
Service agreement revenue | 1,759,207 | 1,705,199 | ||||||
Total operating revenues | 8,334,702 | 7,359,914 | ||||||
Operating expenses: |
||||||||
Salaries and benefits | 5,643,206 | 4,884,889 | ||||||
Shareholder salaries | 165,439 | 442,921 | ||||||
Other operating expenses | 1,960,789 | 1,712,275 | ||||||
7,769,434 | 7,040,085 | |||||||
Total operating income | 565,268 | 319,829 | ||||||
Other income (expense): |
||||||||
Interest income | 3,914 | 3,607 | ||||||
Interest expense | (20,991 | ) | (31,491 | ) | ||||
Loss from investment in real estate (Note 7) | (3,020 | ) | (1,770 | ) | ||||
Other expense | (3,537 | ) | (4,686 | ) | ||||
(23,634 | ) | (34,340 | ) | |||||
Net income | $ | 541,634 | $ | 285,489 |
See accompanying notes.
3
Balance, December 31, 2012 | $ | 209,605 | ||
Distributions | (226,515 | ) | ||
Net income | 285,489 | |||
Balance, December 31, 2013 | 268,579 | |||
Distributions | (111,479 | ) | ||
Net income | 541,634 | |||
Balance, December 31, 2014 | $ | 698,734 |
See accompanying notes.
4
2014 | 2013 | |||||||
Operating activities |
||||||||
Net income | $ | 541,634 | $ | 285,489 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
Depreciation | 220,641 | 227,970 | ||||||
Loss on investment in real estate | 3,020 | 1,770 | ||||||
Decrease (increase) in prepaid insurance | 15,363 | (1,466 | ) | |||||
Decrease (increase) in patient and other receivables | (146,892 | ) | 122,927 | |||||
Decrease (increase) in other assets | 1,006 | (5,144 | ) | |||||
Increase (decrease) in accounts payable and accrued expenses | 186,246 | (162,264 | ) | |||||
Net cash provided by operating activities | 821,018 | 469,282 | ||||||
Investing activities |
||||||||
Purchases of property and equipment | (119,924 | ) | (24,664 | ) | ||||
Capital contributed to investment in real estate | (3,020 | ) | (1,770 | ) | ||||
Net cash used in investing activities | (122,944 | ) | (26,434 | ) | ||||
Financing activities |
||||||||
Proceeds from line of credit | | 65,000 | ||||||
Principal payments on line of credit | (85,000 | ) | (115,000 | ) | ||||
Principal payments on long-term debt and capital leases obligations | (104,243 | ) | (110,849 | ) | ||||
Distributions paid to shareholders | (111,479 | ) | (226,515 | ) | ||||
Net cash used in financing activities | (300,722 | ) | (387,364 | ) | ||||
Net increase in cash and cash equivalents | 397,352 | 55,484 | ||||||
Cash and cash equivalents at beginning of year | 324,341 | 268,857 | ||||||
Cash and cash equivalents at end of year | $ | 721,693 | $ | 324,341 | ||||
Supplemental disclosures |
||||||||
Interest paid | $ | 22,610 | $ | 31,618 | ||||
Non-cash investing and financing activity: |
||||||||
Medical equipment acquired through capital lease obligations | $ | 77,747 | $ | |
See accompanying notes.
5
Medac Health Services, P.A. (the Company) provides urgent healthcare services through four locations in North Carolina. The Company also provides occupational healthcare, workers compensation management services, and outsourced staffing services.
The accounting and reporting policies conform to accounting principles generally accepted in the United States of America and the prevailing practices within the healthcare industry. The significant accounting policies used in preparing and presenting the financial statements are summarized below.
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company considers its most significant estimates to be the collectability of accounts receivable, including the determination of the allowance for doubtful accounts and contractual adjustments. Actual results could differ from these estimates.
The Company considers all depository accounts at financial institutions to be cash and cash equivalents. At various times during the two years ending December 31, 2014, the Company maintained balances in excess of balances insured by the Federal Deposit Insurance Corporation. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.
Patient accounts receivable consist of amounts due from insurance companies and patients in the Wilmington, North Carolina area. The Company generally does not require collateral with the extension of credit; as such, the majority of its receivables are unsecured. Patient accounts receivable are recorded net of expected contractual adjustments and an allowance for doubtful accounts.
The Company maintains an allowance for doubtful accounts based on managements assessment of collectability, current economic conditions, and prior experience. The Company determines if patient accounts receivable are past-due based on the service date; however, the Company does not charge interest on past-due accounts. The Company charges off patient accounts receivable if management considers the collection of the outstanding balances to be doubtful.
While management uses available information in estimating the Companys allowances for contractual adjustments and doubtful accounts, changes in the reimbursable contract rates and the composition of the patient treatments could result in further changes in the carrying amounts of patient receivables. As such, it is reasonably possible that the estimated patient receivables may change materially in the near term. The amount of the change that is reasonably possible, however, cannot be estimated.
Property and equipment are stated at cost. Expenditures for property and equipment which substantially increase the useful lives or values of existing assets are capitalized and subsequently depreciated. Expenditures for repairs and maintenance are expensed as incurred.
Depreciation is provided primarily using the straight-line method over the estimated useful lives of the assets, which range from 3 to 15 years. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, based on undiscounted cash flows. There were no impairment charges recorded for the years ended December 31, 2014 and 2013.
6
The Company has agreements with various third-party payers that provide for payments to the Company at amounts different from its established rates. New patient revenue is reported at the estimated net realizable amounts from patients, third-party payers and others for services rendered, including estimated retroactive adjustments under reimbursement agreements with third-party payers, at the time services are rendered. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered, and adjusted in future periods as final settlements are determined.
The Company leases certain employees to a staffing service under an agreement in exchange for a fee. Administrative services are also provided to the staffing service under the agreement for a monthly fee. Revenue related to the agreement is recorded during the period when the services are completed.
Advertising costs are charged to operations when incurred and totaled $166,237 and $95,391 for the years ended December 31, 2014 and 2013, respectively.
The Company maintains insurance for protection from losses resulting from professional liability claims. The policy covers the first $1,000,000 per claim and $3,000,000 in the aggregate annually.
The Company, with the consent of its shareholders, has elected to be taxed under sections of federal and state income tax law which provide that, in lieu of corporate income taxes, the shareholders separately account for their pro rata shares of items of the Companys income, deductions, losses and credits. As a result of this election, no income taxes have been recognized in the accompanying financial statements.
As required by Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 740-10-50-15, Unrecognized Tax Benefit Related Disclosures, the Company assesses its tax positions to determine if any positions are uncertain. The Company has analyzed its filing positions open to review and believes all significant positions have a more-likely-than-not likelihood of being upheld based on technical merits. The Company is open to audit by various taxing authorities for the prior three years.
The Company has agreements with governmental and other third-party payers that provide for payments to the Company at amounts different from its established rates. Contractual adjustments under third-party reimbursement programs represent the differences between the Companys billings at established rates for services and amounts reimbursed by third-party payers. A summary of the basis of reimbursement with major third-party payers is as follows:
| Medicare Services rendered to Medicare program beneficiaries are recorded at prospectively determined rates. These rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors. |
| Commercial and health maintenance organization (HMO) The Company has entered into agreements with certain commercial insurance carriers, HMOs, and preferred provider organizations. Billing methodologies under these agreements include discounts from established charges and prospectively determined rates. |
7
Below is a summary of patient service revenues for the years ended December 31:
2014 | 2013 | |||||||
Gross patient service revenue | $ | 10,677,700 | $ | 9,582,173 | ||||
Provision for contractual adjustments | (4,102,205 | ) | (3,927,458 | ) | ||||
Patient service revenue, net | $ | 6,575,495 | $ | 5,654,715 |
A summary of patient accounts receivable as of December 31 is as follows:
2014 | 2013 | |||||||
Patient accounts receivable | $ | 889,288 | $ | 719,128 | ||||
Estimated allowance for contractual adjustments and doubtful accounts | (355,715 | ) | (287,651 | ) | ||||
Patient accounts receivable, net | $ | 533,573 | $ | 431,477 |
The Company has a $200,000 revolving line of credit with a bank. Interest is payable monthly at the daily LIBOR rate plus 2.20% (2.38% and 2.36% at December 31, 2014 and 2013, respectively), adjusted daily, through June 2016. At December 31, 2014 and 2013, $0 and $85,000 was borrowed on the line, respectively. Borrowings under the line are secured by substantially all assets of the Company.
Long-term debt consists of the following at December 31:
2014 | 2013 | |||||||
Promissory note requiring monthly principal payments of $3,830 plus interest at the 1 month LIBOR plus 2.20% (2.35% at December 31, 2014), with balance due November 2016.(a) | $ | 777,490 | $ | 823,450 | ||||
Promissory note requiring monthly payments of $1,544 including interest at 4.30%, with balance due August 2015.(b)(c) | 92,888 | 108,576 | ||||||
870,378 | 932,026 | |||||||
Less current maturities | 138,848 | 61,648 | ||||||
Long-term debt, excluding current maturities | $ | 731,530 | $ | 870,378 |
(a) | This loan is secured by substantially all assets of the Company. |
(b) | This loan is secured by certain property as described in Note 7. |
(c) | The Company adopted FASB Accounting Standards Update (ASU) No. 2013-04, Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date, which prescribes the accounting for joint and several liability arrangements. This guidance requires an entity to measure its obligation resulting from joint and several liability arrangements for which the total amount under the arrangement is fixed at the reporting date, as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. Based on the agreement with the partners in the unincorporated joint venture described in Note 7, the Company has recognized one-third of the promissory note in the financial statements, which represents the amounts the Company with the other borrowers agreed to pay, and the amounts the Company expects to pay. |
8
Aggregate maturities of long-term debt are as follows:
Year ending December 31, |
||||
2015 | $ | 138,848 | ||
2016 | 731,530 | |||
$ | 870,378 |
The Company leases certain medical equipment under capital lease arrangements. Cost of the equipment under the capital lease was $77,747 and $234,765 as of December 31, 2014 and 2013, respectively. Accumulated amortization related to the leased assets was $9,406 and $206,304 as of December 31, 2014 and 2013, respectively. Amortization expenses related to the leased assets are included within depreciation expense.
The following is a schedule of the future required payments under capital lease agreements:
Year ending December 31, |
||||
2015 | $ | 17,023 | ||
2016 | 17,023 | |||
2017 | 17,023 | |||
2018 | 17,023 | |||
2019 | 7,438 | |||
Total | 75,530 | |||
Less amount representing interest | 5,874 | |||
Present value of minimum lease payments | 69,656 | |||
Less current portion | 14,744 | |||
Long-term capital lease obligation | $ | 54,912 |
The Company leases office space for one of its locations from Seamist Management, LLC (Seamist), which is owned by the same shareholders of the Company, under an operating lease expiring in December 2015. Rent paid to Seamist was $152,864 and $148,412 for the years ended December 31, 2014 and 2013, respectively.
The Company is a co-borrower on two term loans that financed the building held by Seamist. The loans are secured by the building as well as substantially all assets of the Company and have a floating interest rate at the 1-month LIBOR plus 2.20% and mature in December 2016. At December 31, 2014 and 2013, the remaining principal balance was approximately $4,566,000 and $4,833,000, respectively.
In addition to the Company, Seamist leases portions of the building to unrelated parties. If the unrelated parties become delinquent on payments or do not renew their leases, Seamist could become delinquent on the loans, and the Company may be required to assume payment of the loans. As of December 31, 2014, the Company does not expect to be responsible for any future loan payments related to Seamist.
The Company has elected to apply FASB ASU No. 2014-07, Applying Variable Interest Entities Guidance to Common Control Leasing Arrangements, which provides an elective accounting alternative for private companies to forego the application of the variable interest entity (VIE) guidance to certain lessor legal entities under common control. As such, Seamist is not reflected in these financial statements as a VIE.
9
In addition, the Company leases office space and various office equipment for its other two locations under noncancelable operating leases expiring through June 2025. Rental expense on these leases was $242,072 and $260,000 for the years ended December 31, 2014 and 2013, respectively.
Following is a schedule of the future minimum lease payments required under operating lease agreements:
Year ending December 31 |
Related Party | Other | Total | |||||||||
2015 | $ | 157,449 | $ | 262,523 | $ | 419,972 | ||||||
2016 | | 265,973 | 265,973 | |||||||||
2017 | | 272,498 | 272,498 | |||||||||
2018 | | 275,571 | 275,571 | |||||||||
2019 | | 106,640 | 106,640 | |||||||||
Thereafter | | 625,513 | 625,513 | |||||||||
$ | 157,449 | $ | 1,808,718 | $ | 1,966,167 |
The Company maintains a 401(k) Profit Sharing Plan, under which eligible employees can defer up to the lesser of 90% of their compensation or the maximum amount allowed by law. Matching contributions are made at the discretion of the Companys Board of Directors. The Companys contributions are $76,242 and $46,045 for the years ended December 31, 2014 and 2013, respectively.
The Company grants credit without collateral to its patients, which consist primarily of local residents which are insured under third-party payer agreements. Significant concentrations of gross patient receivables as of December 31 and gross patient revenues for the years ended December 31 are as follows:
2014 | 2013 | |||||||||||||||
Revenues | Receivables | Revenues | Receivables | |||||||||||||
Blue Cross/Blue Shield | 17 | % | 25 | % | 14 | % | 21 | % | ||||||||
Medicare | 5 | % | 16 | % | 6 | % | 11 | % | ||||||||
United Healthcare | 3 | % | 11 | % | 6 | % | 12 | % |
10
The Company has a one-third interest in an unincorporated joint venture. The Company accounts for its investment using the equity method. During the years ended December 31, 2014 and 2013, the Company contributed capital of $3,020 and $1,770 to the investee, respectively, and recognized $3,020 and $1,770 of investee loss, respectively. Condensed financial information for the joint venture as of and for the years ended December 31 is as follows:
2014 | 2013 | |||||||
Assets: |
||||||||
Land and improvements | $ | 465,516 | $ | 465,516 | ||||
Liabilities and equity: |
||||||||
Accrued expenses | $ | 4,802 | $ | 4,802 | ||||
Equity | 460,714 | 460,714 | ||||||
Total liabilities and equity: | $ | 465,516 | $ | 465,516 | ||||
Net loss | $ | 9,060 | $ | 5,310 |
Subsequent to year-end, the Companys interest in the unincorporated joint venture was distributed to the shareholders of the Company.
The Company has entered into an administrative and staffing agreement with ECEP II, P.A. (ECEP) for the purpose of leasing certain Company staff to area medical facilities. Certain shareholders of the Company are also shareholders of ECEP. The Company provides administrative support to ECEP in exchange for a monthly fee, as well as staffing in exchange for a fee dependent on the number of hours and staff levels provided. Revenues recognized from ECEP for the years ended December 31, 2014 and 2013 are $1,759,207 and $1,705,199, respectively. As of December 31, 2014, the Company has a receivable from ECEP of $44,796 related to the reimbursement of expenses.
Additionally, see Note 4 for description of relationship and transactions with Seamist.
The Company evaluated all subsequent events through July 16, 2015, the date the financial statements were available to be issued.
11
2014 | 2013 | |||||||
Advertising | $ | 166,237 | $ | 95,391 | ||||
Billing | 150,877 | 140,258 | ||||||
Building and equipment rent | 396,576 | 381,155 | ||||||
Depreciation | 220,641 | 227,970 | ||||||
Dues, licenses, and memberships | 25,306 | 27,890 | ||||||
General and administrative | 319,618 | 240,569 | ||||||
Insurance | 30,275 | 31,358 | ||||||
Laboratory fees | 135,637 | 124,193 | ||||||
Medical library | 429 | 45 | ||||||
Medical supplies | 181,541 | 159,609 | ||||||
Medical wastes | 3,089 | 3,059 | ||||||
Pharmaceuticals | 155,363 | 114,362 | ||||||
Professional fees | 45,231 | 43,342 | ||||||
Repairs and maintenance | 54,036 | 38,634 | ||||||
Utilities | 68,463 | 71,960 | ||||||
X-ray | 7,470 | 12,480 | ||||||
$ | 1,960,789 | $ | 1,712,275 |
See accompanying notes.
12
Exhibit 99.2
To the Shareholders
Medac Health Services, P.A.
Wilmington, North Carolina
We have compiled the accompanying balance sheet of Medac Health Services, P.A. as of September 30, 2015, and the related statements of income and cash flows for the nine month period then ended. We have not audited or reviewed the accompanying financial statements and, accordingly, do not express an opinion or provide any assurance about whether the financial statements are in accordance with accounting principles generally accepted in the United States of America.
Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America and for designing, implementing, and maintaining internal control relevant to the preparation and fair presentation of the financial statements.
Our responsibility is to conduct the compilation in accordance with Statements on Standards for Accounting and Review Services issued by the American Institute of Certified Public Accountants. The objective of a compilation is to assist management in presenting financial information in the form of financial statements without undertaking to obtain or provide any assurance that there are no material modifications that should be made to the financial statements.
/s/ LWBJ, LLP
November 23, 2015
West Des Moines, Iowa
See accompanying notes.
1
Assets |
||||
Current assets: |
||||
Cash and cash equivalents | $ | 729,470 | ||
Patient accounts receivable, net | 616,727 | |||
Receivable from related party | 44,796 | |||
Prepaid insurance | 3,188 | |||
Other current assets | 1,800 | |||
Total current assets | 1,395,981 | |||
Other assets, noncurrent | 5,696 | |||
5,696 | ||||
Property and equipment: |
||||
Leasehold improvements | 1,765,424 | |||
Furniture | 218,909 | |||
Computer equipment | 145,047 | |||
Medical equipment | 238,748 | |||
Office equipment | 145,326 | |||
Other equipment | 184,202 | |||
2,697,656 | ||||
Less accumulated depreciation | 1,805,796 | |||
891,860 | ||||
Total assets | $ | 2,293,537 | ||
Liabilities and shareholders' equity |
||||
Current liabilities: |
||||
Current portion of capital lease obligations | $ | 20,368 | ||
Current maturities of long-term debt | 45,960 | |||
Accounts payable | 412,723 | |||
Accrued salaries, wages, and benefits | 254,853 | |||
Other accrued expenses | 155,236 | |||
Total current liabilities | 889,140 | |||
Capital lease obligations, net of current portion | 64,839 | |||
Long-term debt, less current maturities | 693,230 | |||
Total liabilities | 1,647,209 | |||
Shareholders' equity: |
||||
Common stock, $1 par value; 100,000 shares authorized; 1,200 shares issued and outstanding | 1,200 | |||
Additional paid-in capital | 71,913 | |||
Retained earnings | 573,215 | |||
Total shareholders' equity | 646,328 | |||
Total liabilities and shareholders' equity | $ | 2,293,537 |
See accompanying notes.
2
Patient service revenue, net | $ | 6,108,810 | ||
Service agreement revenue | 1,391,356 | |||
Total operating revenues | 7,500,166 | |||
Operating expenses: |
||||
Salaries and benefits | 5,033,080 | |||
Facilities | 397,362 | |||
Medical supplies | 342,113 | |||
Other operating expenses | 1,087,919 | |||
Depreciation and amortization | 157,083 | |||
7,017,557 | ||||
Total operating income | 482,609 | |||
Other income (expense): |
||||
Interest income | 1,374 | |||
Rental income | 37,410 | |||
Interest expense | (15,860 | ) | ||
Other expense | (7,307 | ) | ||
15,617 | ||||
Net income | $ | 498,226 |
See accompanying notes.
3
Operating activities |
||||
Net income | $ | 498,226 | ||
Adjustments to reconcile net income to net cash provided by operating activities: |
||||
Depreciation | 157,083 | |||
Increase in patient and other receivables | (83,155 | ) | ||
Decrease in other assets | 2,743 | |||
Decrease in accounts payable and accrued expenses | 95,145 | |||
Net cash provided by operating activities | 670,042 | |||
Investing activities |
||||
Purchases of property and equipment | (78,055 | ) | ||
Net cash used in investing activities | (78,055 | ) | ||
Financing activities |
||||
Principal payments on long-term debt and capital leases obligations | (26,396 | ) | ||
Distributions paid to shareholders | (557,814 | ) | ||
Net cash used in financing activities | (584,210 | ) | ||
Net increase in cash and cash equivalents | 7,777 | |||
Cash and cash equivalents at beginning of year | 721,693 | |||
Cash and cash equivalents at end of period | $ | 729,470 | ||
Supplemental disclosures |
||||
Interest paid | $ | 15,860 | ||
Non-cash investing and financing activity: |
||||
Disbribution of real estate held as investment, net of related debt | $ | 65,931 |
See accompanying notes.
4
Medac Health Services, P.A. (the Company) provides urgent healthcare services through four locations in North Carolina. The Company also provides occupational healthcare, workers' compensation management services, and outsourced staffing services.
The accounting and reporting policies conform to accounting principles generally accepted in the United States of America and the prevailing practices within the healthcare industry. The significant accounting policies used in preparing and presenting the financial statements are summarized below.
On July 31, 2015, the Company entered into an asset purchase agreement with ACSH Medical Management, LLC (ACSH) to sell significantly all of the assets of the Company to ACSH for $5,600,000. Consummation of the transaction is subject to ACSH receiving financing. The transaction is expected to close in the fourth quarter of 2015.
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company considers its most significant estimates to be the collectability of accounts receivable, including the determination of the allowance for doubtful accounts and contractual adjustments. Actual results could differ from these estimates.
The Company considers all depository accounts at financial institutions to be cash and cash equivalents. At various times during the nine months ended September 30, 2015, the Company maintained balances in excess of balances insured by the Federal Deposit Insurance Corporation. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.
Patient accounts receivable consist of amounts due from insurance companies and patients in the Wilmington, North Carolina area. The Company generally does not require collateral with the extension of credit; as such, the majority of its receivables are unsecured. Patient accounts receivable are recorded net of expected contractual adjustments and an allowance for doubtful accounts.
The Company maintains an allowance for doubtful accounts based on management's assessment of collectability, current economic conditions, and prior experience. The Company determines if patient accounts receivable are past-due based on the service date; however, the Company does not charge interest on past-due accounts. The Company charges off patient accounts receivable if management considers the collection of the outstanding balances to be doubtful.
While management uses available information in estimating the Company's allowances for contractual adjustments and doubtful accounts, changes in the reimbursable contract rates and the composition of the patient treatments could result in further changes in the carrying amounts of patient receivables. As such, it is reasonably possible that the estimated patient receivables may change materially in the near term. The amount of the change that is reasonably possible, however, cannot be estimated.
Property and equipment are stated at cost. Expenditures for property and equipment which substantially increase the useful lives or values of existing assets are capitalized and subsequently depreciated. Expenditures for repairs and maintenance are expensed as incurred.
See accompanying notes.
5
Depreciation is provided primarily using the straight-line method over the estimated useful lives of the assets, which range from 3 to 15 years. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, based on undiscounted cash flows. There were no impairment charges recorded during the nine months ended September 30, 2015.
The Company has agreements with various third-party payers that provide for payments to the Company at amounts different from its established rates. New patient revenue is reported at the estimated net realizable amounts from patients, third-party payers and others for services rendered, including estimated retroactive adjustments under reimbursement agreements with third-party payers, at the time services are rendered. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered, and adjusted in future periods as final settlements are determined.
The Company leases certain employees to a staffing service under an agreement in exchange for a fee.
Administrative services are also provided to the staffing service under the agreement for a monthly fee. Revenue related to the agreement is recorded during the period when the services are completed.
Advertising costs are charged to operations when incurred and totaled $145,980 for the nine months ended September 30, 2015.
The Company maintains insurance for protection from losses resulting from professional liability claims. The policy covers the first $1,000,000 per claim and $3,000,000 in the aggregate annually.
The Company, with the consent of its shareholders, has elected to be taxed under sections of federal and state income tax law which provide that, in lieu of corporate income taxes, the shareholders separately account for their pro rata shares of items of the Company's income, deductions, losses and credits. As a result of this election, no income taxes have been recognized in the accompanying financial statements.
As required by Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 740-10-50-15, Unrecognized Tax Benefit Related Disclosures, the Company assesses its tax positions to determine if any positions are uncertain. The Company has analyzed its filing positions open to review and believes all significant positions have a more-likely-than-not likelihood of being upheld based on technical merits.
The Company has agreements with governmental and other third-party payers that provide for payments to the Company at amounts different from its established rates. Contractual adjustments under third-party reimbursement programs represent the differences between the Company's billings at established rates for services and amounts reimbursed by third-party payers. A summary of the basis of reimbursement with major third-party payers is as follows:
| Medicare Services rendered to Medicare program beneficiaries are recorded at prospectively determined rates. These rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors. |
See accompanying notes.
6
| Commercial and health maintenance organization (HMO) The Company has entered into agreements with certain commercial insurance carriers, HMOs, and preferred provider organizations. Billing methodologies under these agreements include discounts from established charges and prospectively determined rates. |
Below is a summary of patient service revenues for the nine months ended September 30, 2015:
Gross patient service revenue | $ | 10,014,443 | ||
Provision for contractual adjustments | (3,905,633 | ) | ||
Patient service revenue, net | $ | 6,108,810 |
A summary of patient accounts receivable as of September 30, 2015 is as follows:
Patient accounts receivable | $ | 1,011,028 | ||
Estimated allowance for contractual adjustments and doubtful accounts | (394,301 | ) | ||
Patient accounts receivable, net | $ | 616,727 |
The Company has a $200,000 revolving line of credit with a bank. Interest is payable monthly at the daily LIBOR rate plus 2.20%, adjusted daily, through June 2016. There was no outstanding balance on the line at September 30, 2015. Borrowings under the line are secured by substantially all assets of the Company.
Long-term debt consists of the following at September 30, 2015:
Promissory note requiring monthly principal payments of $3,830 plus interest at the 1 month LIBOR plus 2.20%, with balance due November 2016.(a) | $ | 739,190 | ||
Less current maturities | 45,960 | |||
Long-term debt, excluding current maturities | $ | 693,230 |
(a) | This loan is secured by substantially all assets of the Company. |
Aggregate maturities of long-term debt are as follows:
Year ending September 30, | ||||
2016 | $ | 45,960 | ||
2017 | 693,230 | |||
$ | 739,190 |
The Company leases certain medical equipment under capital lease arrangements. Cost of the equipment under the capital lease was $105,582 as of September 30, 2015. Accumulated amortization related to the leased assets was $23,652 as of September 30, 2015. Amortization expenses related to the leased assets are included within depreciation expense.
See accompanying notes.
7
The following is a schedule of the future required payments under capital lease agreements:
Year ending September 30, | ||||
2016 | $ | 23,118 | ||
2017 | 23,118 | |||
2018 | 23,118 | |||
2019 | 17,788 | |||
2020 | 5,079 | |||
Total | 92,221 | |||
Less amount representing interest | 7,014 | |||
Present value of minimum lease payments | 85,207 | |||
Less current portion | 20,368 | |||
Long-term capital lease obligation | $ | 64,839 |
The Company leases office space for one of its locations from Seamist Management, LLC (Seamist), which is owned by the same shareholders of the Company, under an operating lease expiring in December 2015. Rent paid to Seamist was $109,815 for the nine months ended September 30, 2015.
The Company is a co-borrower on two term loans that financed the building held by Seamist. The loans are secured by the building as well as substantially all assets of the Company and have a floating interest rate at the 1-month LIBOR plus 2.20% and mature in December 2016. At September 30, 2015, the remaining principal balance was approximately $4,365,000.
In addition to the Company, Seamist leases portions of the building to unrelated parties. If the unrelated parties become delinquent on payments or do not renew their leases, Seamist could become delinquent on the loans, and the Company may be required to assume payment of the loans. As of September 30, 2015, the Company does not expect to be responsible for any future loan payments related to Seamist.
The Company has elected to apply FASB ASU No. 2014-07, Applying Variable Interest Entities Guidance to Common Control Leasing Arrangements, which provides an elective accounting alternative for private companies to forego the application of the variable interest entity (VIE) guidance to certain lessor legal entities under common control. As such, Seamist is not reflected in these financial statements as a VIE.
In addition, the Company leases office space and various office equipment for its other two locations under noncancelable operating leases expiring through June 2025. Rental expense on these leases was $230,426 and for the nine months ended September 30, 2015.
Following is a schedule of the future minimum lease payments required under operating lease agreements:
Year ended September 30: |
Related Party | Other | Total | |||||||||
2016 | $ | 39,362 | $ | 386,509 | $ | 463,621 | ||||||
2017 | | 393,075 | 393,075 | |||||||||
2018 | | 398,978 | 398,978 | |||||||||
2019 | | 268,924 | 268,924 | |||||||||
2020 | | 230,385 | 230,385 | |||||||||
Thereafter | | 1,124,415 | 1,124,415 | |||||||||
$ | 39,362 | $ | 2,802,286 | $ | 2,841,648 |
See accompanying notes.
8
The Company maintains a 401(k) Profit Sharing Plan, under which eligible employees can defer up to the lesser of 90% of their compensation or the maximum amount allowed by law. Matching contributions are made at the discretion of the Company's board of directors. The Company's contributions are $62,105 for the nine months ended September 30, 2015.
The Company grants credit without collateral to its patients, which consist primarily of local residents which are insured under third-party payer agreements. Significant concentrations of gross patient receivables as of September 30, 2015 and gross patient revenues for the nine months ended September 30, 2015 are as follows:
Revenues | Receivables | |||||||
Blue Cross/Blue Shield | 18 | % | 23 | % |
In March 2015, the Company's interest in the unincorporated joint venture was distributed to Seamist, along with the related debt.
FASB ASC Topic 805-50, Business Combinations, requires that transfers of assets and liabilities between entities under common control be recorded at the carrying amount of the distributing entity, thus, the Company recorded no gain or loss on the transfer.
The Company has entered into an administrative and staffing agreement with ECEP II, P.A. (ECEP) for the purpose of leasing certain Company staff to area medical facilities. Certain shareholders of the Company are also shareholders of ECEP. The Company provides administrative support to ECEP in exchange for a monthly fee, as well as staffing in exchange for a fee dependent on the number of hours and staff levels provided. Revenues recognized from ECEP for the nine months ended September 30, 2015 are $1,391,356. As of September 30, 2015, the Company has a receivable from ECEP of $44,796 related to the reimbursement of expenses.
Additionally, see Note 4 for description of relationship and transactions with Seamist.
The Company evaluated all subsequent events through November 23, 2015, the date the financial statements were available to be issued.
See accompanying notes.
9
Exhibit 99.3
On July 31, 2015, ACSH Medical Management LLC, or ACSH Management, a wholly-owned subsidiary of American CareSource Holdings, Inc. (the Company) entered into an Asset Purchase Agreement with Medac Health Services, P.A., or Medac, and its shareholders to purchase certain assets used in the operation of its four urgent care centers located in the greater Wilmington, North Carolina area (as described in the Asset Purchase Agreement, which was filed on August 6, 2015 in a Current Report on Form 8-K with the Securities and Exchange Commission).
On May 8, 2014, ACSH Urgent Care of Georgia, LLC., a wholly owned subsidiary of the Company, completed the purchase of substantially all the assets of two urgent care centers, from CorrectMed Locust Grove, LLC, CorrectMed Scott, LLC, CorrectMed, LLC and other seller parties (collectively, CorrectMed).
The unaudited pro forma condensed balance sheet as of September 30, 2015 combines the historical consolidated balance sheet of the Company and the historical combined balance sheet of Medac to illustrate the estimated effect of the acquisition on the Company's financial statements as if it had occurred on September 30, 2015. Since the acquisition of CorrectMed occurred prior to September 30, 2015, the financial position of CorrectMed is included within the historical balance sheet of the Company.
The unaudited pro forma condensed consolidated statement of operations for the nine months ended September 30, 2015 combines the historical consolidated statements of operations of the Company with the historical statement of operations of Medac as if the acquisition of Medac had occurred on January 1, 2014. The unaudited pro forma condensed consolidated statement of operations for the year ended December 31, 2014 combines the consolidated statement of operations of the Company (including CorrectMed since the acquisition date) with the historical statement of operations of Medac for the year ended December 31, 2014 and the historical statement of operations for CorrectMed from January 1, 2014 to May 8, 2014 (acquisition date), as if the acquisitions of Medac and CorrectMed had occurred on January 1, 2014. The unaudited pro forma condensed consolidated financial statements are based on certain estimates and assumptions made with respect to the combined operations of the Company, Medac, and CorrectMed, which we believe are reasonable. The unaudited pro forma condensed consolidated statements of operations are presented for illustrative purposes only and do not purport to be indicative of the results of operations of the Company, Medac or CorrectMed that actually would have been achieved had the acquisitions of Medac or CorrectMed been completed on the assumed dates, or to project the Company's results of operations for any future date or period.
The Medac and CorrectMed transactions are being accounted for using the acquisition method of accounting for business combinations in accordance with generally accepted accounting principles in the United States. Under this method, the total consideration transferred to consummate the acquisitions are being allocated to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the closing dates of the acquisitions. The acquisition method of accounting requires extensive use of estimates and judgements to allocate the consideration transferred to the identifiable tangible and intangible assets acquired and liabilities assumed. Accordingly, the allocation of the consideration transferred in the unaudited pro forma condensed consolidated financial statements is preliminary and will be adjusted upon completion of the final valuation of the assets acquired and liabilities assumed. Such adjustments could be significant. The final valuation is expected to be completed as soon as practicable and when all information to complete the acquisition is obtained but no later than 12 months after the closing date of the acquisition. The unaudited condensed consolidated pro forma statements of operations do not include costs that the Company may incur to integrate Medac with the Companys current operations, and these costs may be material.
The historical consolidated financial statements have been adjusted in the unaudited pro forma condensed consolidated financial statements to give effect to pro forma events that are (i) directly attributable to the acquisitions, (ii) factually supportable, and (iii) expected to continually impact the combined results of the
1
Company, Medac, and CorrectMed. The pro forma financial statements are limited to the aforementioned criteria and only provide information as the effect of the particular transactions, and do not include secondary or indirect effects. Thus adjustments related to cost efficiencies, economies of scale and those made to evaluate the transactions are not included as they are not directly attributable to the transactions. In addition, the unaudited pro forma condensed consolidated financial statements were derived from, and should be read in conjunction with, the information for the nine months ended September 30, 2015 included in the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2015 and the annual report on the Form 10-K for the year ended December 31, 2014.
The historical condensed financial information regarding Medac and CorrectMed that is included in this report has been prepared by, and is the responsibility of the Company. In addition, we are in the process of reviewing Medac's financial statement classification for conformity with the Company's classifications. As a result of this review, it may be necessary to make, among other changes, additional reclassifications to the consolidated information on a prospective basis.
The statements contained in these notes that are not historical facts are forward-looking statements that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements, such as our expectations for future sales results or future expense changes compared with previous periods, are only predictions. These forward-looking statements may be generally identified by the use of forward-looking words and phrases such as will, intends, may, believes, anticipates, should, and expects, and are based on our current expectations or beliefs concerning future events that involve risks and uncertainties. Actual events or results may differ materially as a result of risk and uncertainties as described in Item 1A. Risk Factors in the Company's Quarterly Report on Form 10-Q for the nine months ended September 30, 2015 and annual report on Form 10-K for the year ended December 31, 2014, other risks referenced in our Securities and Exchange Commission filings, or other unanticipated risks. We disclaim any obligation to update publicly any forward-looking statements whether as a result of new information, future events or otherwise.
2
Historical Company |
Historical CorrectMed(1) |
Historical Medac |
Pro Forma As Adjusted Adjustments |
Pro Forma As Adjusted |
||||||||||||||||
Net revenues: |
||||||||||||||||||||
Ancillary network | $ | 23,146 | $ | | $ | | $ | | $ | 23,146 | ||||||||||
Urgent and primary care | 3,906 | 1,124 | 6,576 | | 11,606 | |||||||||||||||
Service agreement revenue | | | 1,759 | | 1,759 | |||||||||||||||
Total net revenues | 27,052 | 1,124 | 8,335 | | 36,511 | |||||||||||||||
Operating expenses: |
||||||||||||||||||||
Ancillary network provider payments | 16,241 | | | | 16,241 | |||||||||||||||
Ancillary network administrative fees | 1,127 | | | | 1,127 | |||||||||||||||
Ancillary network operating costs under Management Services Agreement | 903 | | | | 903 | |||||||||||||||
Salaries, wages, benefits and taxes | 8,157 | | 5,809 | | 13,966 | |||||||||||||||
Other operating expenses | 5,910 | 1,191 | 1,739 | (140 | )(7) | 8,700 | ||||||||||||||
Management fees | | 145 | | (145 | )(2) | | ||||||||||||||
Depreciation and amortization | 866 | 85 | 221 | 40 | (3) | 1,212 | ||||||||||||||
Total operating expenses | 33,204 | 1,421 | 7,769 | (245 | ) | 42,149 | ||||||||||||||
Operating (loss) | (6,152 | ) | (297 | ) | 566 | 245 | (5,638 | ) | ||||||||||||
Other (income) expense: |
||||||||||||||||||||
Interest (income) expense, net | 115 | 29 | 17 | 7 | (4) | 168 | ||||||||||||||
Loss on warrant liability, net of deferred loan fees amortization | 534 | | | | 534 | |||||||||||||||
Loss from investment in real estate | | | 3 | (3 | )(5) | | ||||||||||||||
(Gain)/loss on disposal of fixed assets | (108 | ) | | | | (108 | ) | |||||||||||||
Other expense | | | 4 | | 4 | |||||||||||||||
Total other (income) expense | 541 | 29 | 24 | 4 | 598 | |||||||||||||||
Income/(loss) before income taxes (benefit) | (6,693 | ) | (326 | ) | 542 | 241 | (6,236 | ) | ||||||||||||
Income tax expense (benefit) | 70 | | | | 70 | |||||||||||||||
Net income (loss) | $ | (6,763 | ) | $ | (326 | ) | $ | 542 | $ | 241 | $ | (6,306 | ) | |||||||
Basic and diluted net loss per common share | $ | (1.05 | ) | $ | (0.37 | )(6) | ||||||||||||||
Basic and diluted weighted-average common shares outstanding | 6,407 | 16,050 | (6) |
Pro forma Adjustments and Assumptions
(1) | To record 2014 results from operations for CorrectMed prior to the Companys acquisition on May 8, 2014, for period January 1, 2014 through May 8, 2014. |
(2) | To eliminate $145,000 of management fees paid by CorrectMed to an affiliate, which payments were discontinued after acquisition. |
(3) | To record estimated amortization expense of intangibles valued at acquisition date and expected to be amortized over 5 years. |
3
(4) | To eliminate $21,000 of interest expense related to debt expected to be satisfied by Medac or assumed by an affiliate of Medac at the closing of the transaction and to record $28,000 for 12 months of interest expense related to the $560,000 promissory note included as part of the aggregate consideration. Interest is payable at 5% annually and due 18 months after closing date. |
(5) | To eliminate loss from investment in real estate recognized in connection with a shareholder distribution made prior to closing. |
(6) | Pro forma as adjusted after giving effect to the issuance and sale of 9,642,857 Class A Units and 750 Class B Units in the offering consummated December 9, 2015. Does not include the shares of common stock that may be issued under the warrants to be issued in such offering. The net loss per share is calculated on a two class participating securities method with losses allocated to the participating preferred stock. The basic net loss per share for the preferred stock was $(526.31) per share. |
(7) | To eliminate $140,000 of transaction costs related to the CorrectMed acquisition that were incurred by the Company. |
4
Historical Company |
Historical Medac |
Pro Forma As Adjusted Adjustments |
Pro Forma As Adjusted |
|||||||||||||
Net revenues: |
||||||||||||||||
Ancillary network | $ | 15,640 | $ | | | $ | 15,640 | |||||||||
Urgent and primary care | 7,251 | 6,109 | | 13,360 | ||||||||||||
Service agreement revenue | | 1,391 | | 1,391 | ||||||||||||
Total net revenues | 22,891 | 7,500 | | 30,391 | ||||||||||||
Operating expenses: |
||||||||||||||||
Ancillary network provider payments | 11,598 | | | 11,598 | ||||||||||||
Ancillary network administrative fees | 799 | | | 799 | ||||||||||||
Ancillary network other operating costs | 2,985 | | | 2,985 | ||||||||||||
Ancillary network perpaid write-off | 487 | | | 487 | ||||||||||||
Salaries, wages, contract medical professional fees and related expenses | 8,331 | 5,033 | | 13,364 | ||||||||||||
Facility expenses | 1,048 | 397 | 1,445 | |||||||||||||
Medical supplies | 623 | 342 | 965 | |||||||||||||
Other operating expenses | 5,344 | 1,088 | (59 | )(4) | 6,373 | |||||||||||
Intangible asset impairment | 520 | | | 520 | ||||||||||||
Depreciation and amortization | 857 | 157 | 30 | (1) | 1,044 | |||||||||||
Total operating expenses | 32,592 | 7,017 | (29 | ) | 39,580 | |||||||||||
Operating (loss) | (9,701 | ) | 483 | 29 | (9,189 | ) | ||||||||||
Other (income) expense: |
||||||||||||||||
(Gain) on cancellation of acquisition promissory note | (289 | ) | | | (289 | ) | ||||||||||
Rental income | | (37 | ) | | (37 | ) | ||||||||||
Interest expense: |
||||||||||||||||
Interest (income) expense, net | 277 | 15 | 5 | (2) | 297 | |||||||||||
(Gain)/loss on warrant liability, net of deferred loan fees amortization | (489 | ) | | | (489 | ) | ||||||||||
Other expense | | 7 | | 7 | ||||||||||||
Total other (income) expense and interest expense | (501 | ) | (15 | ) | 5 | (511 | ) | |||||||||
Loss before income taxes | (9,200 | ) | 498 | 24 | (8,678 | ) | ||||||||||
Income tax expense | 10 | | | 10 | ||||||||||||
Net income (loss) | $ | (9,210 | ) | $ | 498 | $ | 24 | $ | (8,688 | ) | ||||||
Basic net loss per common share | $ | (1.35 | ) | $ | (0.49 | ) | ||||||||||
Diluted net loss per common share | $ | (1.60 | ) | $ | (0.60 | ) | ||||||||||
Basic weighted-average common shares outstanding | 6,847 | 16,490 | (3) | |||||||||||||
Diluted weighted-average common shares outstanding | 6,913 | 16,556 | (3) |
Pro forma Adjustments and Assumptions
(1) | To record estimated amortization expense of intangibles valued at acquisition date and expected to be amortized over 5 years. |
5
(2) | To eliminate $16,000 of interest expense related to debt expected to be satisfied by Medac or assumed by an affiliate of Medac at the closing of the transaction and to record $21,000 for 9 months of interest expense related to the $560,000 promissory note included as part of the aggregate consideration. Interest is payable at 5% annually and due 18 months after closing date. |
(3) | Pro forma as adjusted after giving effect to the issuance and sale of 9,642,857 Class A Units and 750 Class B Units in the offering consummated December 9, 2015. Does not include the shares of common stock that may be issued under the warrants to be issued in such offering. The net loss per share is calculated on a two class participating securities method with losses allocated to the participating preferred stock. The basic and diluted net loss per share for the preferred stock was $(706.95) and $(856.46), respectively. The preferred stock was anti-dilutive for the diluted net loss per share calculation. |
(4) | To elimate $59,000 of transaction costs related to the Medac acquisition that were incurred by the Company. |
6
Historical Company |
Pro Forma(1) | Historical Medac |
Pro Forma As Adjusted Adjustments |
Pro Forma As Adjusted |
||||||||||||||||
ASSETS |
||||||||||||||||||||
Current assets: |
||||||||||||||||||||
Cash and cash equivalents | $ | 197 | $ | 6,727 | $ | 729 | $ | (5,769 | )(2) | $ | 1,687 | |||||||||
Accounts receivable | 2,969 | 2,969 | 662 | | 3,631 | |||||||||||||||
Prepaid expenses and other current assets | 775 | 775 | 5 | | 780 | |||||||||||||||
Deferred income taxes | 6 | 6 | | | 6 | |||||||||||||||
Total current assets | 3,947 | 10,477 | 1,396 | (5,769 | ) | 6,104 | ||||||||||||||
Property and equipment, net | 3,921 | 3,921 | 892 | | 4,813 | |||||||||||||||
Other assets: |
||||||||||||||||||||
Deferred income taxes | 12 | 12 | | | 12 | |||||||||||||||
Deferred loan fees, net | 1,625 | 1,625 | | | 1,625 | |||||||||||||||
Deferred offering costs | 310 | | | | | |||||||||||||||
Other non-current assets | 104 | 104 | 5 | | 109 | |||||||||||||||
Intangible assets, net | 705 | 705 | | 202 | (3) | 907 | ||||||||||||||
Goodwill | 6,113 | 6,113 | | 3,834 | (4) | 9,947 | ||||||||||||||
Total other assets | 8,869 | 8,559 | 5 | 4,036 | 12,600 | |||||||||||||||
Total assets | $ | 16,737 | $ | 22,957 | $ | 2,293 | $ | (1,733 | ) | $ | 23,517 | |||||||||
LIABILITIES AND STOCKHOLDERS' EQUITY |
||||||||||||||||||||
Current liabilities: |
||||||||||||||||||||
Lines of credit | $ | 5,000 | $ | 5,000 | $ | | $ | | $ | 5,000 | ||||||||||
Due to ancillary network service providers | 2,900 | 2,900 | | | 2,900 | |||||||||||||||
Due to HealthSmart, ancillary network | 672 | 672 | | | 672 | |||||||||||||||
Accounts payable | 944 | 944 | 413 | (413 | )(5) | 944 | ||||||||||||||
Accrued liabilities | 2,062 | 2,062 | 410 | (235 | )(5)(7) | 2,237 | ||||||||||||||
Current portion of long-term debt | 351 | 351 | 46 | (46 | )(5) | 351 | ||||||||||||||
Capital lease obligations, current portion | 130 | 130 | 20 | (20 | )(5) | 130 | ||||||||||||||
Total current liabilities | 12,059 | 12,059 | 889 | (714 | ) | 12,234 | ||||||||||||||
Long-term liabilities: |
||||||||||||||||||||
Line of credit | 5,800 | 5,800 | | | 5,800 | |||||||||||||||
Promissory notes and notes payable | | | 693 | (133 | )(6) | 560 | ||||||||||||||
Capital lease obligations | 1,666 | 1,666 | 65 | (65 | )(5) | 1,666 | ||||||||||||||
Warrant derivative liability | 1,670 | 31 | | | 31 | |||||||||||||||
Other long-term liabilities | 356 | 356 | | | 356 | |||||||||||||||
Total long-term liabilities | 9,492 | 7,853 | 758 | (198 | ) | 8,413 | ||||||||||||||
Total liabilities | 21,551 | 19,912 | 1,647 | (912 | ) | 20,647 | ||||||||||||||
Commitments and contingencies | | | | | |
7
Historical Company |
Pro Forma(1) | Historical Medac |
Pro Forma As Adjusted Adjustments |
Pro Forma As Adjusted |
||||||||||||||||
Stockholders' equity (deficit): |
||||||||||||||||||||
Preferred stock, $1,000 stated value; 10,000 shares authorized, none issued, actual; 10,000 shares authorized, 750 issued and outstanding, as adjusted and pro forma as adjusted | | 750 | | | 750 | |||||||||||||||
Common stock, $0.01 par value; 40,000 shares authorized; 6,952 issued and outstanding, historical and 16,595 outstanding on a pro forma basis respectively | 69 | 165 | 1 | (1 | )(5) | 165 | ||||||||||||||
Additional paid-in capital | 26,188 | 33,201 | 72 | (72 | )(5) | 33,201 | ||||||||||||||
Retained earnings (accumulated deficit) | (31,071 | ) | (31,071 | ) | 573 | (748 | )(5)(7) | (31,246 | ) | |||||||||||
Total stockholders' equity (deficit) | (4,814 | ) | 3,045 | 646 | (821 | ) | 2,870 | |||||||||||||
Total liabilities and stockholders' equity (deficit) | $ | 16,737 | $ | 22,957 | $ | 2,293 | $ | (1,733 | ) | $ | 23,517 |
Pro forma Adjustments and Assumptions
(1) | The pro forma balance sheet data gives effect to (i) our issuance and sale of 9,642,857 Class A Units and 750 Class B Units in the offering consummated December 9, 2015 at the public offering price of $.70 per Class A Unit and $1,000 per Class B Unit and (ii) increase in stockholders' equity due to the receipt from certain holders of the Company's warrants issued on July 30, 2014, December 4, 2014 and August 12, 2015 (holders of at least $1,639,000 in warrant derivative liability value as valued on September 30, 2015) of waivers to any further exercise price anti-dilution protection, and corresponding decrease in the warrant derivative liability. Does not include the shares of common stock that may be issued under the warrants to be issued in such offering. After deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us of $1,280,000, the offering provides us estimated net proceeds of $6,220,000. Offering expenses of $310,000 had been incurred and capitalized as of September 30, 2015, thus these deferred offering costs have been reclassified against additional paid-in capital and shown as an increase in net proceeds of $310,000 to $6,530,000, in the pro forma condensed consolidated balance sheet as of September 30, 2015. This does not include the underwriters option to purchase additional securities. |
(2) | Represents a decrease of $5,140,000 for the cash portion of the purchase price payable to Medac at closing and a reduction from $729,000 to $100,000, for the net cash required to be on hand at closing. The preliminary Medac purchase price allocation is as follows: |
Cash | $ | 100,000 | ||
A/R | 662,000 | |||
Prepaids & Other Current Assets | 5,000 | |||
Other Non-Current Assets | 5,000 | |||
Fixed Assets | 892,000 | |||
Intangible Assets | 202,000 | |||
Goodwill | 3,834,000 | |||
Total | $ | 5,700,000 |
8
(3) | Represents estimated portion of the Medac purchase price allocable to amortizable intangibles, which are expected to be amortized over 5 years. The amount, and related amortizable intangles, are subject to change based on the results of the final valuation of assets acquired and liabilities assumed, which is expected to be completed within the 12 months following the closing of the acquisition. |
(4) | Represents the excess of the Medac purchase price over the fair value of the assets acquired and liabilities assumed (goodwill). This amount, and related amortizable intangibles, are subject to change based on the results of the final valuation of assets acquired and liabilites assumed, which is expected to be completed within the 12 months following the acquisition. |
(5) | To eliminate liabilites to be satisfied by Medac or assumed by an affiliate of Medac at closing and eliminate equity. |
(6) | To eliminate $693,000 note to be satisfied by Medac or assumed by an affiliate of Medac at closing and record $560,000 promissory note to be paid by the Company to Medac as part of the purchase price at closing, which note is due 18 months after closing date. |
(7) | To accrue $175,000 in estimated transaction cost to be incurred to complete the Medac acquisition. |
9